» Articles » PMID: 23687122

Disease-specific Molecular Events in Cortical Multiple Sclerosis Lesions

Overview
Journal Brain
Specialty Neurology
Date 2013 May 21
PMID 23687122
Citations 136
Authors
Affiliations
Soon will be listed here.
Abstract

Cortical lesions constitute an important part of multiple sclerosis pathology. Although inflammation appears to play a role in their formation, the mechanisms leading to demyelination and neurodegeneration are poorly understood. We aimed to identify some of these mechanisms by combining gene expression studies with neuropathological analysis. In our study, we showed that the combination of inflammation, plaque-like primary demyelination and neurodegeneration in the cortex is specific for multiple sclerosis and is not seen in other chronic inflammatory diseases mediated by CD8-positive T cells (Rasmussen's encephalitis), B cells (B cell lymphoma) or complex chronic inflammation (tuberculous meningitis, luetic meningitis or chronic purulent meningitis). In addition, we performed genome-wide microarray analysis comparing micro-dissected active cortical multiple sclerosis lesions with those of tuberculous meningitis (inflammatory control), Alzheimer's disease (neurodegenerative control) and with cortices of age-matched controls. More than 80% of the identified multiple sclerosis-specific genes were related to T cell-mediated inflammation, microglia activation, oxidative injury, DNA damage and repair, remyelination and regenerative processes. Finally, we confirmed by immunohistochemistry that oxidative damage in cortical multiple sclerosis lesions is associated with oligodendrocyte and neuronal injury, the latter also affecting axons and dendrites. Our study provides new insights into the complex mechanisms of neurodegeneration and regeneration in the cortex of patients with multiple sclerosis.

Citing Articles

Proteomic analysis reveals candidate molecules to mediate cortical pathology and identify possible biomarkers in an animal model of multiple sclerosis.

Silva B, Leal M, Farias M, Nava A, Galvan D, Fernandez E Front Immunol. 2025; 16:1505459.

PMID: 40018028 PMC: 11864942. DOI: 10.3389/fimmu.2025.1505459.


Immunoexcitoxicity as the possible major pathophysiology behind multiple sclerosis and other autoimmune disorders.

Blaylock R Surg Neurol Int. 2025; 16:26.

PMID: 39926461 PMC: 11799683. DOI: 10.25259/SNI_1114_2024.


Machine learning for refining interpretation of magnetic resonance imaging scans in the management of multiple sclerosis: a narrative review.

Szekely-Kohn A, Castellani M, M Espino D, Baronti L, Ahmed Z, Manifold W R Soc Open Sci. 2025; 12(1):241052.

PMID: 39845718 PMC: 11750376. DOI: 10.1098/rsos.241052.


Understanding the role of potential biomarkers in attenuating multiple sclerosis progression via multiomics and network-based approach.

Shriwash N, Aiman A, Singh P, Basir S, Shamsi A, Shahid M PLoS One. 2024; 19(12):e0314428.

PMID: 39700118 PMC: 11658499. DOI: 10.1371/journal.pone.0314428.


Should We Consider Neurodegeneration by Itself or in a Triangulation with Neuroinflammation and Demyelination? The Example of Multiple Sclerosis and Beyond.

Perdaens O, van Pesch V Int J Mol Sci. 2024; 25(23.

PMID: 39684351 PMC: 11641818. DOI: 10.3390/ijms252312637.


References
1.
Tzartos J, Friese M, Craner M, Palace J, Newcombe J, Esiri M . Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2007; 172(1):146-55. PMC: 2189615. DOI: 10.2353/ajpath.2008.070690. View

2.
Sawcer S, Hellenthal G, Pirinen M, Spencer C, Patsopoulos N, Moutsianas L . Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476(7359):214-9. PMC: 3182531. DOI: 10.1038/nature10251. View

3.
Polman C, OConnor P, Havrdova E, Hutchinson M, Kappos L, Miller D . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):899-910. DOI: 10.1056/NEJMoa044397. View

4.
Wegner C, Esiri M, Chance S, Palace J, Matthews P . Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 2006; 67(6):960-7. DOI: 10.1212/01.wnl.0000237551.26858.39. View

5.
van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra C, van der Valk P . Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008; 45(12):1729-37. DOI: 10.1016/j.freeradbiomed.2008.09.023. View